JPH0482831A - Anti-neoplasmic agent - Google Patents
Anti-neoplasmic agentInfo
- Publication number
- JPH0482831A JPH0482831A JP2195495A JP19549590A JPH0482831A JP H0482831 A JPH0482831 A JP H0482831A JP 2195495 A JP2195495 A JP 2195495A JP 19549590 A JP19549590 A JP 19549590A JP H0482831 A JPH0482831 A JP H0482831A
- Authority
- JP
- Japan
- Prior art keywords
- neoplasmic
- complex
- cisplatin
- agent
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、有機ロジウム錯体を含む抗腫瘍剤に関するも
のである。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to an antitumor agent containing an organorhodium complex.
（従来技術とその問題点）
で示される有機ロジウム錯体を有効成分として含有して
いることを特徴とする抗腫瘍剤である。(Prior Art and its Problems) This is an antitumor agent characterized by containing the organorhodium complex shown below as an active ingredient.
以下、本発明を明らかにするために実施例によりその詳
細を説明する。EXAMPLES Hereinafter, in order to clarify the present invention, details thereof will be explained using examples.
（実施例）
有機ロジウム錯体として、ビス［（２，３，５゜６−η
）−ビシクロ［２，２，１］へブタ−２゜５−ジエン］
ジーμｍクロロジロシウム錯体を合成した。(Example) As an organic rhodium complex, bis[(2,3,5°6-η
)-bicyclo[2,2,1]buta-2゜5-diene]
A G-μm chlorodirosium complex was synthesized.
この有機ロジウム錯体の物理化学的性質は、ｍ、 ｐ
Ｃａｌｃｄ ２４０°ＣＦｏｕｎｄ ２０７°ＣＲ
ｈ含有率 Ｃａ１ｃｄ ４４．７％ Ｆｏｕｎｄ
４１，６％溶解度 アルコール、水、有機溶媒にほ
とんど溶けないものである。The physicochemical properties of this organorhodium complex are m, p
Calcd 240°CFound 207°CR
h content Ca1cd 44.7% Found
Solubility: 41.6% Almost insoluble in alcohol, water, and organic solvents.
この有機ロジウム錯体の抗腫瘍スクリーニング方法とし
てマウス実験によった。As an antitumor screening method for this organorhodium complex, we conducted experiments on mice.
■）使用動物：ＣＤＦ、マウス（１群 ６びき）２）使
用ガン種： Ｐ ３８８１Ｊンパ球性白血病細胞１０６
細胞を腹空内投与したもの。■) Animals used: CDF, mice (6 mice per group) 2) Cancer type used: P 3881J lymphocytic leukemia cells 106
Cells administered intraperitoneally.
３）抗腫瘍剤の投与法： ＣＤＦ、マウスにＰ２Ｓ５を
接種後、第１日日と第５日日に薬剤を腹空内投与する。3) Administration method of anti-tumor agent: After inoculating CDF and P2S5 into mice, the drug is administered intraperitoneally on the 1st and 5th day.
４）評価方法：無処理群の生存日数に対する投与群の生
存日数の比（Ｔ／Ｃ％）が合成物では１２０％以上を有
効Ｐとする、アメリカＮＣＩのプロトコールに従った。4) Evaluation method: The protocol of the American NCI was followed, in which the ratio (T/C%) of the survival days of the treated group to the survival days of the untreated group was 120% or more for a compound as effective P.
なお、比較のためにシスプラチンを用いた。Note that cisplatin was used for comparison.
その結果を下表で示す。The results are shown in the table below.
（発明の効果）
今回ＬｅｕｋｅｍｉａＰ３８８を用いて、ＣＤＦ１マウ
ススクリーニングテストを行ったところ、当核ロジウム
錯体はシスプラチン以上の制ガン性をしめしたことを特
徴とする。(Effects of the Invention) When a CDF1 mouse screening test was conducted using Leukemia P388, this nuclear rhodium complex was characterized in that it exhibited more anticancer activity than cisplatin.
このことは、ロジウム錯体がシスプラチン等の白金錯体
以上の制ガン性を示すことが期待できるものである。This means that rhodium complexes can be expected to exhibit greater anticancer properties than platinum complexes such as cisplatin.
Claims (1)
いることを特徴とする抗腫瘍剤。(1) An antitumor agent characterized by containing an organorhodium complex represented by the following general formula ▲ Numerical formula, chemical formula, table, etc. ▼ as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2195495A JPH0482831A (en) | 1990-07-24 | 1990-07-24 | Anti-neoplasmic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2195495A JPH0482831A (en) | 1990-07-24 | 1990-07-24 | Anti-neoplasmic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0482831A true JPH0482831A (en) | 1992-03-16 |
Family
ID=16342038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2195495A Pending JPH0482831A (en) | 1990-07-24 | 1990-07-24 | Anti-neoplasmic agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0482831A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003520424A (en) * | 2000-01-14 | 2003-07-02 | アブ アーベー | Capacitor element for power capacitor, power capacitor having the element, and metallized film for power capacitor |
-
1990
- 1990-07-24 JP JP2195495A patent/JPH0482831A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003520424A (en) * | 2000-01-14 | 2003-07-02 | アブ アーベー | Capacitor element for power capacitor, power capacitor having the element, and metallized film for power capacitor |
| JP4869531B2 (en) * | 2000-01-14 | 2012-02-08 | アブ アーベー | Capacitor element for power capacitor, power capacitor having the element, and metallized film for power capacitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kelland et al. | Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes | |
| DE3586759T2 (en) | ANTITUMOR-PLATINUM COMPLEXES. | |
| Montana et al. | The rational design of anticancer platinum complexes: the importance of the structure-activity relationship | |
| DE3685751T2 (en) | HYDROPHOBIC CIS-PLATIN COMPLEXES INCORPORATED IN LIPOSOMES. | |
| Amir et al. | Anticancer activity, DNA-binding and DNA-denaturing aptitude of palladium (II) dithiocarbamates | |
| FI72321B (en) | FOER FARING FRAMSTAELLNING AV NYA VID BEHANDLING AV CANCER ANVAENDBARA PLATINA (IV) -DIAMINKOMPLEXER | |
| CH641758A5 (en) | PLATINUM DIAMINE COMPLEXES AND THEIR USE FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF CANCER. | |
| M. Santos et al. | Recent advances of metallocenes for medicinal chemistry | |
| DE69901177T2 (en) | PLATINUM COMPLEX, THEIR PRODUCTION AND THEIR THERAPEUTIC USE | |
| JPH02795A (en) | 1,2-bis(aminomethyl)cyclobutane-platinum complex compound, its manufacture, drug containing it and having antitumor action, and manufacture of said drug | |
| EP0026813A2 (en) | (N-phosphonoacetyl-L-aspartato) (1,2 diaminocyclohexane) platinum (II) and the sodium, potassium or lithium salts thereof, their preparation and pharmaceutical compositions containing them | |
| DE3630497A1 (en) | CIS-PLATINUM COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | |
| DE69422712T2 (en) | TRIS-PLATINUM COMPLEXES | |
| RU2130941C1 (en) | Trinuclear cationic platinum complexes having antitumor activity, method of preparing thereof, and pharmaceutical compositions containing said complexes | |
| CH658244A5 (en) | NEW PLATINUM COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF MEDICAL PREPARATIONS CONTAINING THEM FOR THE TREATMENT OF CANCER. | |
| Klapötke | Biological activity of organometallic bismuth compounds | |
| CA1273935A (en) | Platinum-intercalative complexes for the treatment of cancer | |
| Cleare et al. | Antitumor platinum complexes: structure-activity relationships | |
| JPH0482831A (en) | Anti-neoplasmic agent | |
| KR100314720B1 (en) | Platinum complex conjugated to cyclotriphosphazene, prepration thereof, and anticancer agent comprising the same | |
| CA2070497C (en) | Novel platinum (ii) complex and antitumor agent | |
| EP1473298B1 (en) | Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions | |
| AU597932B2 (en) | (Gem-heterocyclodimethanamine-N,N') platinum complexes | |
| JPS61249993A (en) | Novel organoplatinum complex and production thereof | |
| JPH0236188A (en) | platinum complex |